Related Experiment Video
Updated: Apr 20, 2026
07:01
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
9.7K
Treatment of resistant epilepsy
William Owen Pickrell1, Phil E M Smith2
1Neurology and Molecular Neuroscience Research Group, College of Medicine, Swansea University, Swansea, UK, and Welsh Epilepsy Centre, University Hospital of Wales, Cardiff, UK.
Clinical Medicine (London, England)
|December 4, 2014
Summary
Approximately 20% of epilepsy patients experience treatment resistance, leading to significant comorbidities. Thorough diagnosis, investigation into causes, and tailored management including surgery, optimized medication, and comorbidity care are crucial for better outcomes.
Area of Science:
- Neurology
- Epilepsy Research
Background:
- Treatment-resistant epilepsy impacts roughly 20% of individuals with epilepsy.
- This condition is associated with significant comorbidities, negatively affecting patient quality of life.
Purpose of the Study:
- To emphasize the importance of accurate epilepsy diagnosis and comprehensive etiological investigation.
- To outline optimal management strategies for treatment-resistant epilepsy.
Main Methods:
- Review of current diagnostic and management protocols for epilepsy.
- Emphasis on early surgical referral when appropriate.
- Discussion of pharmacological optimization and comorbidity management.
Main Results:
- Secure diagnosis and thorough etiological investigation are paramount.
- Early surgical intervention can be beneficial for eligible patients.
- Optimizing anti-epileptic drug therapy and addressing comorbidities like depression are key components of care.
Conclusions:
- Effective management of treatment-resistant epilepsy requires a multi-faceted approach.
- Integrated care addressing neurological and psychological aspects improves patient prognosis.
More Related Videos
Related Concept Videos
01:14Antiepileptic Drugs: Glutamate Antagonists
1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
01:24Epilepsy and Seizures: Overview
1.8K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.8K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.8K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.8K
01:30Electroconvulsive Therapy
2.4K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.4K
01:08Antiepileptic Drugs: Sodium Channel Blockers
2.5K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.5K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K